- Home
- RNP vs PCRX Comparison
RNP vs PCRX Comparison
Compare RNP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- PCRX
- Stock Information
- Founded
- RNP 2003
- PCRX 2006
- Country
- RNP United States
- PCRX United States
- Employees
- RNP N/A
- PCRX N/A
- Industry
- RNP Investment Managers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RNP Finance
- PCRX Health Care
- Exchange
- RNP Nasdaq
- PCRX Nasdaq
- Market Cap
- RNP 1.1B
- PCRX 1.2B
- IPO Year
- RNP N/A
- PCRX 2011
- Fundamental
- Price
- RNP $21.98
- PCRX $25.03
- Analyst Decision
- RNP
- PCRX Buy
- Analyst Count
- RNP 0
- PCRX 7
- Target Price
- RNP N/A
- PCRX $27.14
- AVG Volume (30 Days)
- RNP 117.6K
- PCRX 790.4K
- Earning Date
- RNP 01-01-0001
- PCRX 08-05-2025
- Dividend Yield
- RNP 7.94%
- PCRX N/A
- EPS Growth
- RNP N/A
- PCRX N/A
- EPS
- RNP N/A
- PCRX N/A
- Revenue
- RNP N/A
- PCRX $705,848,000.00
- Revenue This Year
- RNP N/A
- PCRX $7.90
- Revenue Next Year
- RNP N/A
- PCRX $11.02
- P/E Ratio
- RNP N/A
- PCRX N/A
- Revenue Growth
- RNP N/A
- PCRX 2.25
- 52 Week Low
- RNP $15.52
- PCRX $11.16
- 52 Week High
- RNP $21.27
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- RNP 45.50
- PCRX 62.84
- Support Level
- RNP $21.72
- PCRX $24.70
- Resistance Level
- RNP $22.17
- PCRX $25.35
- Average True Range (ATR)
- RNP 0.23
- PCRX 1.07
- MACD
- RNP -0.03
- PCRX 0.37
- Stochastic Oscillator
- RNP 42.07
- PCRX 90.32
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.